Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021

Rhea-AI Summary

Can-Fite BioPharma Ltd. (NYSE American: CANF) announces that Dr. Sari Fishman will present at the BIO Digital Convention on June 10-11 & 14-18, 2021. Can-Fite has secured approximately $20 million from out-licensing agreements for its drug candidates, with potential milestone payments of up to $130 million. The company anticipates key developments, including topline data from Phase III psoriasis and Phase II COVID-19 trials, as well as initiating pivotal trials in liver cancer and NASH by year-end.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s Vice President of Business Development Dr. Sari Fishman will present at the BIO Digital International Convention and participate in one-on-one meetings with potential licensing and distribution partners on June 10-11 & 14-18, 2021. Over 3,800 delegates from 2,300 companies are registered for BIO One-on-One Partnering.

Can-Fite currently has out-licensing agreements for its Namodenoson and Piclidenoson drug candidates in several territories and has received approximately $20 million in upfront and milestone payments to date with additional potential milestone payments of up to approximately $130 million, plus double-digit royalties on net sales following regulatory approval.

“We look forward to productive meetings with potential partners in untapped territories for our drug candidates as we approach several milestones before year-end including announcing topline data from our Phase III psoriasis trial and Phase II COVID-19 study, as well as commencing a pivotal Phase III in liver cancer and a Phase IIb in NASH,” stated Can-Fite CEO Dr. Pnina Fishman.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005228/en/

FAQ

What is the date of Can-Fite's presentation at the BIO Digital Convention?

Can-Fite's presentation at the BIO Digital Convention is scheduled for June 10-11 & 14-18, 2021.

What are the financial highlights mentioned in Can-Fite's recent press release?

Can-Fite has received around $20 million from out-licensing agreements, with potential milestone payments totaling up to approximately $130 million.

What drug candidates is Can-Fite currently developing?

Can-Fite is developing Piclidenoson for psoriasis and COVID-19, and Namodenoson for liver cancer and NASH.

What major milestones does Can-Fite expect to announce by year-end?

Can-Fite expects to announce topline data from its Phase III psoriasis trial and Phase II COVID-19 study, while also commencing Phase III trials for liver cancer and Phase IIb for NASH.

What is the significance of Can-Fite's drug Namodenoson?

Namodenoson is significant as it has received Orphan Drug Designation and Fast Track Designation for hepatocellular carcinoma (HCC), the most common form of liver cancer.